loader image
Friday, July 19, 2024
96.8 F
We Welcome your Press Release
- Advertisement -

BREAKING NEWS: Doctors Hospital at Renaissance Participates in Zika Vaccine Research Trial

Translate to Spanish or other 102 languages!

Mega Doctor News

- Advertisement -

EDINBURG, TX — The Research Institute at Doctors Hospital at Renaissance Health System (DHR) is recruiting healthy people between the ages of 15 and 35 years to participate in a clinical trial in which they might receive an experimental vaccine against the Zika Virus. This research is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) part of the National Institutes of Health (NIH) based in Bethesda, Maryland. The Zika vaccine does not contain live or inactivated Zika virus therefore does not contain infectious material and cannot cause Zika infection. Initial findings indicate the vaccine is safe and able to induce a neutralizing antibody response against the Zika virus. A key goal of the trial at DHR is to determine if the vaccine can effectively prevent disease caused by Zika infection.

A Zika vaccine is urgently needed to prevent the often-devastating birth defects that can result from Zika virus infection during pregnancy. It could also prevent symptoms of the disease such as: low fever with rash, pain in the joints or conjunctivitis. The infection is spread through the Aedes aegypti mosquito, or through sexual contact. There are no specific treatments or vaccines against Zika virus.  From 2007 to 2016, the virus spread to the east, across the Pacific Ocean to the Americas, which led to the Zika virus epidemic 2015-16.

The Research Institute at Renaissance is made up of a group of professionals of excellent academic level and vast experience in research studies under the direction of Lisa Treviño, PhD and other physicians at DHR.

- Advertisement -

Individuals wishing to participate in the study may call 956-362-2380 for more information.

Doctors Hospital at Renaissance continues to be the premier healthcare provider in South Texas.  For more information, please call (956) DOCTORS (362-8677) or visit our website at www.dhr-rgv.com. Join our community @DHRhealth: 

Doctors Hospital at Renaissance participa en un ensayo de investigación
para una vacuna contra el Zika

EDINBURG, TX — El Instituto de Investigación de Doctors Hospital at Renaissance Health System (DHR) está reclutando personas sanas de entre 15 y 35 años de edad para participar en un ensayo clínico en el cual podrían recibir una vacuna experimental contra el virus del Zika. Esta investigación está patrocinada por el Instituto Nacional de Alergias y Enfermedades Infecciosas (National Institute of Allergy and Infectious Diseases, NIAID) que es parte de los Institutos Nacionales de Salud (National Institutes of Health, NIH) con sede en Bethesda, Maryland. La vacuna contra el Zika no contiene el virus vivo o inactivado del Zika, por lo tanto, no contiene material infeccioso y no puede causar la infección del Zika. Los hallazgos iniciales indican que la vacuna es segura y capaz de inducir una respuesta de anticuerpos neutralizante contra el virus del Zika. Un objetivo clave del ensayo en DHR es determinar si la vacuna puede prevenir de manera eficaz la enfermedad causada por la infección por Zika.

Se necesita de manera urgente una vacuna contra el Zika para prevenir los defectos congénitos a menudo devastadores que pueden resultar de la infección por el virus del Zika durante el embarazo. También podría prevenir síntomas de la enfermedad tales como: fiebre baja con sarpullido, dolor en las articulaciones o conjuntivitis. La infección se propaga a través del mosquito Aedes aegypti, o por contacto sexual. No hay tratamientos específicos ni vacunas contra el virus del Zika. Del 2007 al 2016, el virus se extendió hacia el este, a través del Océano Pacífico a las Américas, lo que provocó la epidemia del virus del Zika en el 2015-16.

- Advertisement -

El Instituto de Investigación de Renaissance está compuesto por un grupo de profesionales de excelente nivel académico y vasta experiencia en estudios de investigación bajo la dirección de Lisa Treviño, PhD y otros médicos de DHR.

Las personas que deseen participar en el estudio pueden llamar al 956-362-2380 para obtener más información.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health: Pioneering Alzheimer’s Treatment Breakthrough South of San Antonio

DHR Health, a leader in healthcare innovation, proudly announced today its groundbreaking achievement as the first hospital south of San Antonio to successfully administer Leqembi, an FDA-approved medication for the early treatment of Alzheimer’s disease. This milestone demonstrates their expertise and is a significant advancement in healthcare for the Rio Grande Valley.

FDA Approves First CRISPR Gene Therapy to Treat Sickle Cell Disease

Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.

DHR Health Brownsville Leads the Way in Minimally Invasive Robotic Surgery

DHR Health stands at the forefront of minimally invasive robotic surgery in South Texas, exemplified by its Institute of Robotic Surgery, which successfully completes over 1,000 robotic cases annually. With the recent inauguration of DHR Health Brownsville, this advanced expertise in Minimally Invasive Surgical procedures is extending its reach to the lower Rio Grande Valley. In a groundbreaking milestone last month, Dr. Rene Luna conducted DHR Health Brownsville's inaugural Robotic Surgery.

Pieology Donates 100 Gallons Of Hand Sanitizer To DHR Health

Agustin Guzman and Juan Garza of Pieology said they receive so much support from their communities and businesses, including DHR Health employees who love their pizza, and wanted to give back in a way that offers the hospital system some additional resources to help keep staff and patients protected from the spread of COVID-19 or any other viruses.
- Advertisement -